Kris V. Kowdley

Kris V. Kowdley's AcademicInfluence.com Rankings

Kris V. Kowdley

Philosophy

#4271

World Rank

#6735

Historical Rank

Logic

#1775

World Rank

#2614

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Kris V. Kowdley's Degrees

Doctorate Medicine University of Washington

Why Is Kris V. Kowdley Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kris V. Kowdley's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. (2010) (2333)
Sofosbuvir for previously untreated chronic hepatitis C infection. (2013) (1815)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2015) (1763)
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. (2014) (1153)
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (2013) (1122)
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) (934)
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (2014) (904)
Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases (2011) (700)
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial (2004) (698)
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. (2016) (683)
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study (2015) (676)
Global Epidemiology of Hepatitis B Virus (2004) (647)
Endpoints and clinical trial design for nonalcoholic steatohepatitis (2011) (635)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. (2004) (588)
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis (2018) (481)
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. (2015) (466)
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection (2017) (452)
Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis (2001) (442)
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease (2010) (420)
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease (2012) (415)
Prognostic factors in acute pancreatitis. (2002) (392)
The North American Study for the Treatment of Refractory Ascites. (2003) (391)
ACG Clinical Guideline: Primary Sclerosing Cholangitis (2015) (371)
Etiology and outcome for 295 patients with acute liver failure in the United States. (1999) (370)
Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin (2012) (358)
Iron, hemochromatosis, and hepatocellular carcinoma. (2004) (349)
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. (2014) (346)
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. (2013) (341)
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial (2013) (315)
Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. (1996) (314)
MicroRNAs in Common Human Diseases (2012) (311)
Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. (2015) (299)
High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis (2009) (296)
Exploratory study of oral combination antiviral therapy for hepatitis C. (2013) (291)
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. (2014) (268)
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (254)
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease (2011) (252)
Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll‐like receptor activation (2012) (250)
Depression, fatigue, and functional disability in patients with chronic hepatitis C. (2000) (248)
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (248)
Durability of serologic response after lamivudine treatment of chronic hepatitis B (2003) (240)
Vibration‐Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease (2019) (234)
Prevalence of autoimmune liver disease in Alaska natives (2002) (230)
High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis (2011) (229)
Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. (2003) (216)
Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice (2011) (206)
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. (2016) (205)
Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. (2018) (201)
Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features (1995) (200)
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis (2017) (198)
The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. (2004) (194)
Management of Hemochromatosis (1998) (190)
Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease (2016) (179)
Diagnosis of Hemochromatosis (1998) (178)
A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis (2018) (176)
Serum Ferritin Level Predicts Advanced Hepatic Fibrosis among U.S. Patients with Phenotypic Hemochromatosis (2003) (175)
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease (2019) (175)
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. (2021) (172)
Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. (1995) (169)
Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. (1994) (168)
Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study (2020) (165)
Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis (2013) (164)
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease (2003) (162)
Hepatitis C, iron status, and disease severity: relationship with HFE mutations. (2003) (162)
Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. (2016) (160)
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. (2015) (157)
Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. (2007) (156)
Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease (2018) (154)
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. (2009) (153)
The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. (2008) (149)
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension. (2019) (148)
Endoscopic management of biliary strictures in liver transplant recipients: effect on patient and graft survival. (1998) (146)
Quantitative study of the variability of hepatic iron concentrations. (1999) (144)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis (2019) (140)
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation (2008) (140)
Identification of differentially expressed genes in response to dietary iron deprivation in rat duodenum. (2005) (136)
Natural History of Nonalcoholic Steatohepatitis (2006) (135)
Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials (2015) (135)
Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study (2015) (134)
Review article: the iron overload syndromes (2012) (133)
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. (2019) (132)
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B (2002) (131)
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. (2011) (127)
Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network (2009) (127)
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. (2015) (124)
Method for microRNA isolation from clinical serum samples. (2012) (122)
Management of hemochromatosis. Hemochromatosis Management Working Group. (1998) (119)
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis (2007) (119)
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. (2014) (118)
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. (2019) (114)
Hematologic side effects of interferon and ribavirin therapy. (2005) (113)
Training guideline for use of propofol in gastrointestinal endoscopy. (2004) (113)
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (2005) (113)
Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. (1995) (110)
Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network (2011) (109)
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. (2013) (109)
HFE-associated hereditary hemochromatosis (2009) (108)
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH (2020) (107)
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. (2019) (107)
Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients (2007) (105)
Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. (2003) (104)
Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. (2005) (100)
Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. (2016) (99)
Bile acid changes after high‐dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression (2010) (99)
Iron Metabolism in Nonalcoholic Fatty Liver Disease (2012) (98)
ACG Clinical Guideline: Hereditary Hemochromatosis. (2019) (97)
Changes in Small‐Intestine Permeability with Aging (1995) (97)
Ursodeoxycholic acid therapy in hepatobiliary disease. (2000) (94)
Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. (1995) (93)
End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. (1998) (91)
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow‐up study (2012) (90)
Iron overload in bone marrow transplant recipients (1998) (89)
Vitamin D Deficiency Is Associated With Increased Risk of Non-alcoholic Steatohepatitis in Adults With Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-κB? (2016) (88)
Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β-cell function in humans. (2014) (84)
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial (2021) (84)
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. (2017) (83)
Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis (2014) (83)
The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. (2016) (83)
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
Management of chronic hepatitis B infection (2015) (80)
Association of hepatic iron overload with invasive fungal infection in liver transplant recipients (2006) (79)
Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation (1999) (79)
Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. (2001) (78)
Screening for Hereditary Hemochromatosis in Siblings and Children of Affected Patients: A Cost-Effectiveness Analysis (2000) (78)
Survival after liver transplantation in patients with hepatic iron overload (2005) (78)
Prevalence of hepatic iron overload and association with hepatocellular cancer in end‐stage liver disease: results from the National Hemochromatosis Transplant Registry (2007) (78)
The Management of Chronic Hepatitis B in Asian Americans (2011) (78)
High‐dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis (2011) (76)
Review of direct-acting antiviral agents for the treatment of chronic hepatitis C (2013) (75)
1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS (2012) (74)
Curcumin reduces the toxic effects of iron loading in rat liver epithelial cells (2009) (73)
2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID (2010) (73)
Gastric Varices: An Updated Review of Management (2011) (73)
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis (2020) (72)
The effect of periodic monitoring and feedback on screening colonoscopy withdrawal times, polyp detection rates, and patient satisfaction scores. (2008) (72)
Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis (2019) (72)
Approach to a patient with elevated serum alkaline phosphatase. (2012) (70)
Diagnosis and Management of Primary Biliary Cholangitis (2019) (69)
A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. (2013) (69)
Controversies in the Diagnosis and Management of NAFLD and NASH. (2014) (68)
Real‐world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study (2017) (68)
Vitamin E deficiency and impaired cellular immunity related to intestinal fat malabsorption. (1992) (68)
Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease (2013) (67)
Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. (2005) (67)
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older (2016) (67)
Practice patterns in NAFLD and NASH: real life differs from published guidelines (2016) (66)
Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice (2010) (65)
Quality of life in refractory ascites: Transjugular intrahepatic portal‐systemic shunting versus medical therapy (2005) (64)
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection (2017) (63)
28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC (2011) (63)
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study (2016) (63)
A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. (2005) (61)
A research agenda for curing chronic hepatitis B virus infection (2018) (61)
The role of iron in the pathophysiology and treatment of chronic hepatitis C. (2009) (60)
3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY (2013) (60)
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. (2013) (60)
Renal disease in hepatitis C-positive liver transplant recipients. (1997) (59)
Utility of hepatic iron index in American patients with hereditary hemochromatosis: a multicenter study. (1997) (59)
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. (2019) (58)
Prospective study of the progression of low‐grade dysplasia in ulcerative colitis using current cancer surveillance guidelines (2012) (57)
Infection complicating percutaneous liver biopsy in liver transplant recipients (1997) (57)
Predictors of bile leaks after T-tube removal in orthotopic liver transplant recipients. (1998) (57)
Hereditary Hemochromatosis: Time for Targeted Screening (2008) (57)
Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome (2018) (57)
Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data (2015) (57)
Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States (2007) (57)
Racial differences in the relationship between hepatitis C infection and iron stores (2003) (57)
GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH (2019) (54)
Serum Hepcidin Levels Are Associated With Obesity but Not Liver Disease (2013) (54)
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. (2016) (54)
Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network (2016) (54)
Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. (2011) (53)
Multicenter Validation of Association Between Decline in MRI‐PDFF and Histologic Response in NASH (2020) (53)
Prolonged cholestasis due to trimethoprim sulfamethoxazole. (1992) (53)
Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history (2018) (52)
Acute Viral Hepatitis (Hepatitis A, D, E) (2010) (52)
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response (2019) (52)
Complications after ERCP in patients with primary sclerosing cholangitis. (2008) (51)
Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy? (1998) (50)
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD) (2016) (50)
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. (2018) (49)
Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations (2012) (48)
Cognitive impairment and intracranial calcification in chronic hypoparathyroidism. (1999) (48)
Review article: haemochromatosis. (2002) (48)
Diagnosis and treatment of hereditary hemochromatosis: an update (2013) (48)
Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. (2019) (48)
1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 (2011) (48)
Management of biliary complications following orthotopic liver transplantation (2007) (47)
P0775 : Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population (2015) (47)
Silybin Treatment is Associated With Reduction in Serum Ferritin in Patients With Chronic Hepatitis C (2008) (47)
Recipient and donor factors influence the incidence of graft‐vs.‐host disease in liver transplant patients (2007) (46)
Preference for Colonoscopy Versus Computerized Tomographic Colonography: A Systematic Review and Meta-analysis of Observational Studies (2012) (46)
Determination of hepatitis B phenotype using biochemical and serological markers (2017) (46)
Predicting outcome in primary biliary cirrhosis. (2014) (46)
Extrahepatic biliary stricture associated with cytomegalovirus in a liver transplant recipient (1996) (45)
A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease (2015) (44)
An evaluation of the potential cost‐effectiveness of non‐invasive testing strategies in the diagnosis of significant liver fibrosis (2009) (43)
Evaluating anti‐viral drug selection and treatment duration in HBeAg‐negative chronic hepatitis B: a cost‐effectiveness analysis (2008) (43)
Factors Predictive of Significant Hepatic Fibrosis in Adults With Chronic Hepatitis B and Normal Serum ALT (2008) (43)
Relationship between three commonly used non‐invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non‐alcoholic steatohepatitis (2019) (42)
Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis (2017) (42)
Plasma vitamin K1 level is decreased in primary biliary cirrhosis. (1997) (42)
Differences in Hepatic Phenotype Between Hemochromatosis Patients With HFE C282Y Homozygosity and Other HFE Genotypes (2009) (41)
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. (2019) (41)
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. (2020) (41)
An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States (2021) (41)
Iron Overload Causes Oxidative Stress and Impaired Insulin Signaling in AML-12 Hepatocytes (2013) (41)
13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS (2012) (40)
Relationships between Hepatic Iron Content and Virologic Response in Chronic Hepatitis C Patients Treated with Interferon and Ribavirin (2005) (39)
Current and potential treatments for primary biliary cholangitis. (2019) (39)
Relation Between Vitamin D Status and Nonalcoholic Fatty Liver Disease in Children (2015) (39)
Iron Overload in Patients With Chronic Liver Disease. (2016) (39)
Hepatitis C virus antibodies in systemic lupus erythematosus. (1997) (38)
Guidelines for advanced endoscopic training (2001) (38)
Long-term follow-up after liver transplantation in patients with hepatic iron overload. (1999) (38)
Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients (2017) (38)
Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B (2012) (38)
Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study (2008) (38)
The cost of managing chronic hepatitis B infection: a global perspective. (2004) (36)
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. (2021) (36)
Durable HBeAg and HBsAg seroconversions after lamivudine for chronic hepatitis B (CHB) (2000) (36)
Hemochromatosis gene and nonalcoholic fatty liver disease: a systematic review and meta-analysis. (2011) (35)
Hepatotoxicity of transplant immunosuppressive agents. (1995) (34)
Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States (2015) (34)
Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. (2014) (34)
Urokinase in gastrointestinal tract bleeding. (1988) (33)
The hepcidin circuits act: Balancing iron and inflammation (2011) (32)
Hepatic iron overload in alcoholic end‐stage liver disease is associated with iron deposition in other organs in the absence of HFE‐1 hemochromatosis (2005) (32)
Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study (2007) (32)
Listeria infection after liver transplantation: report of a case and review of the literature (1998) (32)
Cardiopulmonary Consequences of Transjugular Intrahepatic Portosystemic Shunts: Role of Increased Pulmonary Artery Pressure (2004) (31)
Estimation of the human liver volume and configuration using three-dimensional ultrasonography: effect of a high-caloric liquid meal. (1998) (30)
Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. (2017) (30)
Iron in hepatitis C: villain or innocent bystander? (2002) (29)
New developments in the treatment of primary biliary cholangitis – role of obeticholic acid (2017) (29)
Fulminant hepatic failure secondary to neoplastic infiltration of the liver. (2005) (28)
Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study (2016) (27)
Epidemiology of hepatitis B--clinical implications. (2006) (26)
10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB (2012) (26)
The predictors of the presence of varices in patients with primary sclerosing cholangitis (2010) (26)
Obeticholic acid for the treatment of nonalcoholic steatohepatitis (2020) (25)
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. (2021) (25)
Targeted screening for hereditary haemochromatosis in high‐risk groups (2004) (25)
Effect of alcohol on viral hepatitis and other forms of liver dysfunction. (2005) (25)
Delayed hemorrhage after percutaneous liver biopsy. Role of therapeutic angiography. (1994) (25)
Relationship between transferrin-iron saturation, alcohol consumption, and the incidence of cirrhosis and liver cancer. (2007) (25)
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) (2017) (25)
Serum ferritin is associated with non-alcoholic fatty liver disease and decreased Β-cell function in non-diabetic men and women. (2014) (25)
Successful lung transplantation in spite of cystic fibrosis-associated liver disease: a case series. (1997) (24)
Association between metabolic syndrome and liver histology among NAFLD patients without diabetes (2016) (24)
Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications. (2000) (24)
Patient‐Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir (2017) (24)
Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. (2019) (24)
Anemia management in the era of triple combination therapy for chronic HCV. (2012) (24)
Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop (2017) (23)
MicroRNAs in Liver Disease: Bench to Bedside. (2013) (23)
Paradoxical cerebral emboli after transjugular intrahepatic portosystemic shunt and coil embolization for treatment of duodenal varices. (1997) (23)
1011 Final Evaluation of 955 HCV Patients Treated With 12 Week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population (2015) (23)
Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease (2018) (23)
1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY (2011) (23)
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. (2020) (23)
Neoplastic transformation of rat liver epithelial cells is enhanced by non-transferrin-bound iron (2008) (22)
Alcohol's effect on other chronic liver diseases. (2012) (22)
Metal storage disorders: Wilson disease and hemochromatosis. (2014) (22)
1187 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS (2012) (22)
On‐treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3–infected patients treated with daclatasvir and sofosbuvir (2016) (22)
OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC (2011) (22)
Hepatitis C virus re‐treatment in the era of direct‐acting antivirals: projections in the USA (2018) (22)
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. (2020) (22)
Mechanisms of Hepatocyte Detoxification (2012) (21)
Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO (2018) (21)
Obeticholic acid in primary biliary cholangitis: where we stand (2019) (21)
1206 ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS (2012) (21)
Lipids and lipid-activated vitamins in chronic cholestatic diseases. (1998) (21)
Liver transplantation for metabolic liver diseases. (2007) (21)
Increased parenchymal damage and steatohepatitis in Caucasian non‐alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms (2016) (21)
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C? (1999) (20)
Rheumatologic disease and the liver. (2011) (20)
Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis (2019) (19)
The natural history of untreated focal allograft rejection in liver transplant recipients. (1996) (19)
Iron overload related to excessive vitamin C intake. (2003) (19)
Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice. (2009) (19)
Hepcidin Signaling in Health and Disease: Ironing Out the Details (2021) (19)
Hereditary hemochromatosis: genetics, pathogenesis, and clinical management. (2005) (19)
Primary Sclerosing Cholangitis: Epidemiology, Genetics, Diagnosis, and Current Management (2020) (18)
Portal vein thrombosis after hematopoietic cell transplantation: frequency, treatment and outcome (2002) (18)
Nonalcoholic steatohepatitis: a twenty-first century epidemic? (2006) (18)
Liver involvement in patients with solid tumors of nonhepatic origin. (2002) (17)
The role of iron in nonalcoholic fatty liver disease: the story continues. (2010) (17)
Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection (2016) (17)
Primary placement of Palmaz long medium stents in transjugular intrahepatic portosystemic shunts. (2000) (17)
Airway obstruction complicating esophageal stent placement in two post-pneumonectomy patients. (2004) (17)
Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis? (2016) (17)
Genetic liver disease in adults. Early recognition of the three most common causes. (2000) (17)
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. (2020) (16)
Histologic Evidence of Active Liver Injury in Chronic Hepatitis B Patients With Normal Range or Minimally Elevated Alanine Aminotransferase Levels (2010) (16)
Randomised clinical trial: the safety and efficacy of long‐acting octreotide in patients with portal hypertension (2012) (16)
Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma? (2009) (16)
Neonatal hemochromatosis. (2001) (16)
Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen? (2003) (16)
Isolation and characterization of iron chelators from turmeric (Curcuma longa): selective metal binding by curcuminoids (2017) (16)
Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (2021) (15)
Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation (2018) (15)
Pilot Study of the Relationship Between Histologic Progression and Hepatic Iron Concentration in Chronic Hepatitis C (2003) (15)
The Effects of Alcohol on Other Chronic Liver Diseases. (2016) (15)
Guidelines for training non-specialists in screening flexible sigmoidoscopy. (2000) (14)
High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals (2016) (14)
Update on hepatitis C treatment: systematic review of clinical trials. (2017) (14)
Clinical management of iron overload. (1998) (14)
Persistent hepatitis C virus infection after liver transplantation (1995) (14)
Genetic liver disease in adults (2000) (14)
Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update. (2022) (13)
Factors Associated With Progression and Outcomes of Early-stage Primary Biliary Cholangitis. (2020) (13)
Hereditary hemochromatosis and cancer risk: more fuel to the fire? (2001) (13)
Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network (2017) (13)
High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. (2012) (13)
848 HIGH CONCORDANCE OF SVR4, SVR12, AND SVR24 IN PATIENTS WITH HCV INFECTION WHO HAVE RECEIVED TREATMENT WITH SOFOSBUVIR (2013) (13)
Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort (2019) (13)
Hematologic side effects of PEG interferon and ribavirin. Management with growth factors. (2005) (13)
Serum ferritin as a biomarker for NAFLD: ready for prime time? (2019) (13)
A Pilot Genome‐Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH (2019) (13)
Phenotypic Characteristics and Diagnoses of Patients Referred to an Iron Overload Clinic (2010) (13)
Retrospective Comparison of the Patency of Wallstents and Palmaz Long-Medium Stents Used for TIPS (2000) (13)
Adiponectin--tipping the scales from NAFLD to NASH? (2005) (13)
Chronic Hepatitis C in Elderly Patients: Current Evidence with Direct-Acting Antivirals (2018) (12)
The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma (2016) (12)
EFFECTIVENESS OF 8 OR 12 WEEK LDV/SOF IN TREATMENT-NAÏVE PATIENTS WITH NON-CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK (2016) (12)
Differences In Hepatic Expression of Iron, Inflammation and Stress-Related Genes in Patients with Nonalcoholic Steatohepatitis. (2017) (12)
Hepatic copper content is normal in early primary biliary cirrhosis and primary sclerosing cholangitis (1994) (12)
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms (2022) (12)
No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/Sofosbuvir (LDV/SOF): Real World Data from 2034 Genotype 1 Patients in the Trio Network (2016) (12)
An Update on the Treatment and Follow-up of Patients with Primary Biliary Cholangitis. (2017) (12)
The Association Between Cholecystectomy and Gastroesophageal Reflux Symptoms: A Prospective Controlled Study (2008) (12)
Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art (2021) (12)
Temporary Support for Acute Liver Failure (2002) (12)
Review article: targeted screening for hereditary haemochromatosis in high-risk groups. (2004) (12)
Relationship between gene expression of duodenal iron transporters and iron stores in hemochromatosis subjects. (2010) (12)
6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL (2013) (11)
Metals and the liver (2012) (11)
In search of vulcan: Where are all the iron men (and women)? (2002) (11)
Prediction of varices in patients with cirrhosis: a high-stakes numbers game? (2002) (11)
LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment (2019) (11)
61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL (2013) (11)
Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis (2019) (11)
Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis (2019) (11)
7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3 (2012) (11)
Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection (2015) (11)
Chemokines: potent mediators of hepatic inflammation and fibrosis in chronic liver diseases. (2014) (11)
Room-temperature susceptometry predicts biopsy-determined hepatic iron in patients with elevated serum ferritin. (2012) (11)
Hepatitis B and liver transplantation. (2005) (10)
Curcumin and Turmeric Modulate the Tumor-Promoting Effects of Iron In Vitro (2017) (10)
HBV-specific and global T-cell dysfunction in chronic hepatitis B. (2015) (10)
P1184 : Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis (2015) (10)
Expansion of criteria for liver transplantation in HCC: a slippery slope? (2002) (10)
Sclerosing Cholangitis and Recurrent Pyogenic Cholangitis (2010) (10)
Current and future therapy in haemochromatosis and Wilson’s disease (2003) (10)
Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial (2021) (10)
Is silymarin hepatoprotective in alcoholic liver disease? (2003) (10)
Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis. (2017) (10)
Improvement in liver histology among Asian patients with chronic hepatitis B after long‐term treatment with entecavir (2013) (9)
Su1429 Failure With All-Oral DAA Regimens: Real-World Experience From the TRIO Network (2016) (9)
The importance of screening for hemochromatosis. (2003) (9)
Hepatic and pancreatic involvement in systemic amyloidosis. (1993) (9)
Biting the iron bullet: Endoplasmic reticulum stress adds the pain of hepcidin to chronic liver disease (2010) (9)
Oxidative Stress and p 53 Mutations in the Carcinogenesis of Iron Overload-Associated Hepatocellular Carcinoma (2001) (9)
No Impact of Rass on the High Efficacy of SOF/VEL/VOX for 12 Weeks in Daa-Experienced Patients: An Integrated Resistance Analysis of the Polaris-1 and Polaris-4 Studies (2017) (9)
Public Health Surveillance for Hereditary Hemochromatosis (1998) (9)
1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY (2013) (9)
A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis (2020) (9)
Successful treatment of severe hepatitis C-associated pulmonary vasculitis in a liver transplant recipient. (1998) (9)
Relationship between iron concentration and hepatitis C virus RNA level in liver tissue. (1999) (9)
The cost of treating ribavirin-induced anemia in hepatitis C:the impact of using recombinant human erythropoietin* (2007) (8)
Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH. (2018) (8)
Optimal duration of therapy in HBV-related cirrhosis. (2007) (8)
EFFECTIVENESS OF 12 OR 24 WEEK LDV/SOF AND 12 WEEK LDV/SOF+RBV IN TREATMENT-EXPERIENCED PATIENTS WITH CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK (2016) (8)
Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists (2020) (8)
Advances in the diagnosis and treatment of nonalcoholic steatohepatitis. (2014) (8)
Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. (1997) (8)
Glyceronephosphate O‐acyltransferase as a hemochromatosis modifier gene: Another iron in the fire? (2015) (8)
Risk and natural history of colonic neoplastic progression in patients with primary sclerosing cholangitis and ulcerative colitis (1995) (8)
Current perspectives into the evaluation and management of hepatitis B: a review. (2019) (8)
Unresectable hepatocellular carcinoma: the need for an individualized multidisciplinary approach. (2001) (8)
Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction? (2006) (8)
The Glasgow-Blatchford Bleeding Score identified patients with upper GI bleeding who could be managed as outpatients (2009) (8)
The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. (2019) (7)
progression to bridging fibrosis in non-alcoholic fatty liver disease over 4 years in the Nash Crn : 602 (2013) (7)
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease (2018) (7)
Longitudinal changes in liver stiffness by magnetic resonance elastography (MRE), liver fibrosis, and serum markers of fibrosis in a multi-center clinical trial in nonalcoholic steatohepatitis (NASH) (2017) (7)
Liver transplantation: An “in vivo” model for the pathophysiology of hemochromatosis? (2004) (7)
Extrahepatic manifestations of chronic viral hepatitis. (1995) (7)
ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus (2015) (7)
964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC) (2012) (7)
Iron metabolism and diagnosis of iron overload disorders. (2010) (7)
Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls. (2022) (7)
A Proton Pump Inhibitor a Day Keeps the Iron Away. (2016) (7)
Non-HFE hemochromatosis: Genetics, pathogenesis, and clinical management (2005) (7)
Spontaneous group B streptococcal meningitis in a patient with cirrhosis. (1996) (7)
Hereditary hemochromatosis (2006) (7)
Iron and viral hepatitis (1999) (7)
Allogeneic transplantation, Fas signaling, and dysregulation of hepcidin. (2013) (7)
Iron and HFE mutations in nonalcoholic steatohepatitis: innocent bystanders or accessories to the crime? (2003) (7)
Interferon alfa for chronic hepatitis C: how do we define cure? (1998) (6)
Dendritic cells in NASH: friend or foe? (2013) (6)
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD) (2022) (6)
Abnormal liver test results on routine screening (2004) (6)
Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection (2016) (6)
Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. (2018) (6)
Motion - prophylactic banding of esophageal varices is useful: arguments against the motion. (2002) (6)
A Population‐Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection (2020) (6)
TNF-α in Chronic Hepatitis C: The Smoking Gun? (1999) (6)
Investigational drugs in early phase development for primary biliary cholangitis (2020) (6)
CT-Guided Transfemoral Portocaval Shunt Creation (2001) (6)
Mechanisms and Treatments of Pruritus in Primary Biliary Cholangitis (2019) (6)
Acidophil bodies in nonalcoholic steatohepatitis. (2016) (6)
Hepcidin in HFE-associated hemochromatosis: another piece of the "iron" puzzle. (2004) (6)
Human Liver Cytochrome P450 2D6 Genotype, Full‐length Messenger Ribonucleic Acid, and Activity Assessed with a Novel Cytochrome P450 2D6 Substrate (2004) (6)
938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH (2019) (5)
Alcohol intake and iron overload: Another role for hepcidin? (2007) (5)
Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects. (2011) (5)
Bilirubin is predictive of transplant-free survival even within the normal range in primary biliary cholangitis patients (2017) (5)
842 SOFOSBUVIR SAFETY AND TOLERABILITY IN 741 PATIENTS TREATED FOR UP TO 24 WEEKS (2013) (5)
LP18 : Obeticholic acid for NASH: benefits in a high risk subgroup and the effects of concomitant statin use (2015) (5)
764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study (2014) (5)
Liver Function Tests and Interpretation (2012) (5)
Hereditary hemochromatosis. (2008) (5)
LP10 : Efficacy and safety of vitamin E for nonalcoholic steatohepatitis: Combined analysis of three controlled trials (2015) (5)
Built to last? Durability of lamivudine-induced seroconversion in patients with chronic hepatitis B. (2004) (5)
Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial (2020) (5)
Update on hepatitis C: epidemiology, treatment and resistance to antiviral therapies. (2015) (5)
Extrahepatic Biliary Obstruction (2010) (5)
10 Future developments in endoscopic imaging (1995) (5)
High-Dose Vitamin C and Iron Overload (2004) (5)
Behavioral Patterns of Total Serum Bilirubin Prior to Major Clinical Endpoints in 3529 Patients with Primary Biliary Cholangitis (2016) (5)
475 SAPPHIRE I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 631 Treatment-Naïve Adults With Hepatitis C Virus Genotype 1 (2014) (5)
952 LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC) (2012) (4)
An “ironic” case of mistaken identity? (1992) (4)
IS LAMIVUDINE BENEFICIAL IN HBSAG+ PATIENTS AWAITING LIVER TRANSPLANTATION? EXPERIENCE IN 182 NORTH AMERICAN PATIENTS. (1999) (4)
Kinetic Analyses of Antiviral Suppression by NS5A Inhibitors Reveal Early and Potent Inhibition of Viral Assembly and Release of Infectious Virus The rs2294918 K434E PNPLA3 Polymorphism is associated with Nonalcoholic Fatty Liver and Steatohepatitis (2013) (4)
All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients with Advanced Fibrosis or Cirrhosis: An Analysis of Ally-3 and Ally-3+ (2016) (4)
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in nonalcoholic fatty liver disease. (2022) (4)
O132 EFFECTIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA RISK IN PRIMARY BILIARY CIRRHOSIS: RESULTS OF A MULTI-CENTRE INTERNATIONAL STUDY (2014) (4)
Hepatitis vírica aguda (hepatitis A, E y D) (2006) (4)
P374 LONG-TERM TREATMENT OF PRIMARY BILIARY CIRRHOSIS WITH THE FXR AGONIST OBETICHOLIC ACID SHOWS DURABLE EFFICACY (2014) (4)
Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy (2013) (4)
Correction: ACG Clinical Guideline: Hereditary Hemochromatosis. (2019) (4)
Lack of hemodynamic response to long-acting octreotide (Sandostatin LAR) in patients with cirrhosis (2001) (4)
Ledipasvir/Sofosbuvir ± Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the Trio Network (2016) (4)
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection (2019) (4)
Chemoprevention of hepatocellular carcinoma in chronic hepatitis B with lamivudine? (2005) (4)
Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis – even in patients without biochemical improvements (2018) (4)
Obstructive jaundice caused by pancreatic carcinoma in the setting of a normal pancreatogram. (1995) (4)
Gut instinct: Rifaximin for the prevention of hepatic encephalopathy (2010) (4)
P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network (2015) (4)
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis (2022) (4)
Pancreatic fistula without pancreatitis after endoscopic biliary stent placement for bile leak after orthotopic liver transplantation. (1999) (4)
Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Wks in Genotype 1 (GT1) Treatment-Naïve Non-Cirrhotic Patients with HCV Viral Load <6 Million IU/mL (6M); Acomparative Analysis of the Phase-3 ION-3 Data to Real World Effectiveness (2016) (4)
Financial Compensation For Hepatologists in Different Practice Settings (2019) (4)
Long-term entecavir treatment for up to 5 years in Asians with HBEAG-positive nucleos(T)ide naïve chronic hepatitis B: results from ETV-022 and -901 (2010) (4)
Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults (2018) (4)
Asian Pacific Association for Study of the Liver (APASL) (2003) (4)
Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. (2019) (4)
IDDF2018-ABS-0113 The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis (2017) (3)
Alpha1-Antitrypsin Deficiency: A Cause of Chronic Liver Disease. (2020) (3)
P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS (2014) (3)
Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis (2016) (3)
Anxiety and Depression in Patients with Primary Biliary Cholangitis: Current Insights and Impact on Quality of Life (2021) (3)
Treatment of primary biliary cirrhosis. (1993) (3)
Diagnosis and Management of Hereditary Hemochromatosis (1999) (3)
Biliary lipid composition after liver transplantation: effect of allograft function and cyclosporine. (1998) (3)
Iron and hepatitis C (2004) (3)
O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) (2014) (3)
Ledipasvir/Sofosbuvir+/−Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the Trio Network (2016) (3)
TNF-alpha in chronic hepatitis C: the smoking gun? (1999) (3)
OC-030 Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study (2014) (3)
Serum fibrosis markers predict future clinical decompensation in primary biliary cirrhosis better than liver biopsy, bilirubin, or Mayo Risk score (2006) (3)
The GLOBE score identifies PBC patients at increased risk of liver transplantation or death during follow-up (2016) (3)
Real-world treatment utilization and results in the renaissance of HCV Care: analyses of treatment for 7,550 Patients from the TRIO Network (2017) (3)
Clinical practice gaps and challenges in non‐alcoholic steatohepatitis care: An international physician needs assessment (2022) (3)
Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis. (2021) (3)
Cellular microRNA and the tumorigenesis of hepatocellular carcinoma. (2012) (3)
The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time (2017) (3)
OP01 WHO DIES FROM ALCOHOLIC LIVER DISEASE AND WHERE ARE POSSIBLE THERAPEUTIC INTERVENTIONS MISSED? AN ANALYSIS OF 755 DEATHS IN A HEALTH COMMUNITY (2011) (3)
The Prevalence and Presumed Etiology of Elevated Aminotransferase Levels in a Pacific Northwest Tribal Community (2015) (3)
Hemochromatosis: Management of hemochromatosis (2000) (3)
EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study (2020) (3)
Lamivudine for chronic hepatitis B: the magic bullet or just another bright prospect? (1999) (2)
Inherited metabolic liver diseases (1995) (2)
Correlations between Hepatic Morphometric Collagen Content, Histologic Fibrosis Stage, and Serum Markers in Patients with Primary Sclerosing Cholangitis (PSC) (2016) (2)
Inherited liver diseases affecting the adult. (1996) (2)
Mo1557 Evaluation of Effects of Concomitant Medications for NASH and Associated Comorbidities on Histological Improvements With Obeticholic Acid (2016) (2)
Prevalence of primary liver cancer (PLC) and survival in hereditary hemochromatosis (HHC) patients undergoing orthotopic liver transplantation (OLT) (1993) (2)
Utilization of sofosbuvir/velpatasvir in genotype 2–6 HCV: real-world experience from the TRIO network (2017) (2)
Haemochromatosis (2002) (2)
Granulomatous Liver Diseases (2010) (2)
Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid (2022) (2)
Tissue typing for HFE mutations (2002) (2)
Tu1023 Efficacy Evaluation of 24 Week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV Patients; Data From the TRIO Network (2015) (2)
Another link in the iron chain? (2000) (2)
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies (2020) (2)
Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC. (2022) (2)
IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies (2017) (2)
O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY (2014) (2)
Portal Vein Obstruction (2010) (2)
Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis (2020) (2)
P0829 : On-treatment HCVRNA as a predictor of sustained virologic response in HCV genotype 3 infected patients treated with daclatasvir and sofosbuvir: analysis of phase 3 ALLY-3 study (2015) (2)
Alkaline phosphatase normalization is associated with a decreased risk for liver transplantation and death in patients with primary biliary cholangitis (2018) (2)
Biliary strictures in liver transplant recipients (1997) (2)
Vitamin K replacement in osteoporosis associated with cirrhosis: another reason to “eat your vegetables”? (2002) (2)
Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6: 412 (2013) (2)
653 HISTOLOGIC EVIDENCE OF ACTIVE LIVER INJURY IN HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS WITH NORMAL OR MINIMALLY ELEVATED ALANINE TRANSAMINASE (2008) (2)
Liver transplantation for hemochromatosis, Wilson's disease, and other metabolic disorders. (1997) (2)
Iron overload disorders (2022) (2)
Evaluating TIPS trials: the devil is in the details? (1998) (2)
Levels of Alkaline Phosphatase and Bilirubin are Surrogate Endpoints of Outcomes of Patients with Primary Biliary Cirrhosis – an International Follow-up Study Short title : Alkaline phosphatase and bilirubin as surrogate endpoints in PBC (2014) (2)
Sofosbuvir/Velpatasvir in Genotype 2-6 HCV: Real-World Experience from the Trio Network (2017) (2)
Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after one year of treatment (2017) (2)
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients With Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-Infected Patients (2015) (2)
Nonalcoholic Fatty Liver Disease and Steatohepatitis (2010) (2)
Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network (2017) (2)
Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool (2020) (2)
PTU-100 Efficacy of obeticholic acid treatment in patients with primary biliary cholangitis with cirrhosis (2017) (2)
Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-world Experience from the Trio Network (2017) (2)
Hemochromatosis: Chronic viral hepatitis and hemochromatosis (2000) (2)
T1019 A Randomized, Masked, Controlled Study of Omega-3 Polyunsaturated Fatty Acid vs Monounsaturated Fatty Acid Diet Supplementation for the Treatment of Nonalcoholic Fatty Liver Disease (2009) (2)
Appropriate Clinical Genetic Testing of Hemochromatosis Type 2–4, Including Ferroportin Disease (2021) (1)
Evaluation of Effects of Concomitant Medications for Non-Alcoholic Steatohepatitis and Associated Comorbidities on Histological Improvements with Obeticholic Acid (2016) (1)
Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis (2022) (1)
Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV) (2014) (1)
Hypochlorhydria in the elderly (1992) (1)
High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals: 2016 ACG Presidential Poster Award: 868 (2016) (1)
IDDF2019-ABS-0134 Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies (2019) (1)
Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. (2021) (1)
Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR) (2017) (1)
633 Histologic Improvement in Asian Patients With HBeAg(+) and HBeAg(−) Chronic Hepatitis B After Long-Term Treatment With Entecavir: Results From ETV-022, -027 and -901 Studies (2010) (1)
Disruption of Iron Regulation after Radiation and Donor Cell Infusion. (2016) (1)
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH (2022) (1)
Access to HCV Care in the United States: Real-World Experience from the Trio Network (2017) (1)
Treating NAFLD: future prospects. (2006) (1)
Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity (2014) (1)
P1180 : Identification of pbc patients in need of additional therapy during the course of UDCA treatment -an international multicenter study (2015) (1)
Review: antibiotic prophylaxis reduces mortality and bacterial infection in cirrhosis and gastrointestinal bleeding. (2002) (1)
BIOIRON 2001: Proceedings from the World Congress on Iron Metabolism (2002) (1)
Rifaximin maintained remission from hepatic encephalopathy longer than placebo in patients with cirrhosis (2010) (1)
Incidence and Impact of Decompensating Events in Primary Biliary Cirrhosis : Results of an International Follow Up Study of 3030 Patients (2015) (1)
Insulin Resistance and Other Metabolic Risk Factors (2013) (1)
Use of an Automated Health Maintenance Alert is Associated with Increased Hepatitis C Screening Rates in an Integrated Medical Group (2017) (1)
Predictors of Improvement in NAFLD Activity Score on Placebo: A Secondary Analysis of the Flint Trial (2016) (1)
Editorial: frequency of surveillance and survival in hepatocellular carcinoma (2018) (1)
HCV and Iron Excess: The Interaction and how to Handle it (2010) (1)
Characterization of patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a large United States cohort (2018) (1)
Nadolol and isosorbide prevented recurrent variceal bleeding better than did endoscopic ligation in cirrhosis. (2002) (1)
Histologic findings of advanced fibrosis and cirrhosis in patients with NAFLD who have normal aminotransferase levels (2019) (1)
Ras mutations and microsatellite instability detected in ERCP-derived pancreatic juice from patients with pancreatic cancer (1995) (1)
P254: Recipient and donor factors influence the incidence of graft versus host disease in liver transplant patients (2007) (1)
Rebuttal by Drs Dubois and Kowdley (2003) (1)
To band or to block for primary prophylaxis against variceal bleeding? (2006) (1)
Wilson Disease and Hemochromatosis (2014) (1)
Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 7,550 Patients from the Trio Network (2017) (1)
Adding N-acetylcysteine to prednisolone reduced early mortality in severe alcoholic hepatitis (2012) (1)
Biomarkers, imaging and safety in a well-compensated NASH cirrhotic cohort treated with resmetirom, a thyroid hormone receptor beta agonist, for 52 weeks (2022) (1)
Identification of People Infected With Hepatitis C Virus Who Have Never Been Diagnosed. (2019) (1)
Deficiency of a novel biliary epithelial protein crossreactive to colon epithelium in the bile of patients with primary sclerosing cholangitis (PSC) (2001) (1)
ELEVATED a-FETOPROTEIN IN ASSOCIATION WITH LOSS OF SERUM HBeAg (1993) (1)
ACG Clinical Guideline: Hereditary Hemochromatosis (2020) (1)
Chapter 18 – Hemochromatosis (2018) (1)
FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test (2019) (1)
1001 Relationship between hepatic iron content and histological response in chronic hepatitis C (2003) (1)
602 Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 (GT1) Treatment-Naïve (TN) Non-Cirrhotic (NC) Patients with HCV Viral load (VL) <6 million IU/ml (6M); A Comparative Analysis of the Phase-3 ION-3 Data to Real World Effectiveness (RWE) (2016) (1)
Reply: (2013) (1)
Portal Vein Tributaries and Portacaval Anastomoses (2010) (1)
P377 THE FXR AGONIST OBETICHOLIC ACID IMPROVES A TRANSPLANT-FREE SURVIVAL-PROVEN BIOCHEMICAL RESPONSE CRITERION IN PLACEBO CONTROLLED PRIMARY BILIARY CIRRHOSIS STUDIES (2014) (1)
The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis (2023) (1)
High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4 (2017) (1)
603 Access to Therapy in Era of All DAA Regimens: Real-World Experience From the TRIO Network (2016) (1)
Protective effect of ursodiol on neoplastic progression in ulcerative colitis patients with primary sclerosing cholangitis (2000) (1)
Real world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in blacks with HCV: A comparative analysis of clinical trials with real world cohorts. (2017) (1)
Tu1017 Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients Over 70 Years of Age vs Younger HCV Patients; Data From the TRIO Network (2015) (1)
Liver transplantation in the elderly: Is caution warranted? (2001) (1)
An Examination of the Evidence Behind Biochemical Markers in Primary Biliary Cholangitis. (2021) (1)
Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis (2007) (1)
Causes of Portal Hypertension (2010) (1)
Relationship of C282Y HFE Mutations, Hepatic Iron Deposition and Histologic Features in Patients With Nonalcoholic Fatty Liver Disease (2011) (1)
Both Alcoholic and Nonalcoholic Steatohepatitis Is an Emerging Indication for Liver Transplantation in the United States (2020) (0)
Effects of curcumin supplementation on iron overload and liver cancer in a mouse model of hereditary hemochromatosis (829.8) (2014) (0)
Iron contributes to hepatocyte insulin resistance in a cell model of nonalcoholic fatty liver disease (2012) (0)
Physical Diagnosis of Liver Disease (2010) (0)
Surfaces and Bed of the Liver (2010) (0)
Long‐term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States (2022) (0)
Iron and Liver Disease (2012) (0)
Multiorgan iron overload in patients without C282Y mutation (2001) (0)
Comparative Effectiveness of Interventions on Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Network Meta-Analysis (2016) (0)
Su1418 All-Oral Treatment With Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: An Analysis of ALLY-3 and ALLY-3+ (2016) (0)
Machine learning models accurately interpret liver histology and are associated with disease progression in patients with primary sclerosing cholangitis (2020) (0)
Reply to HEP-20-0140 Letter to the Editors: Could Butyrate Be Incorporated With Farnesoid X Receptor Agonist Cilofexor to Enhance Primary Sclerosing Cholangitis Treatment? (2020) (0)
Microrna Profiling Reveals a Signature of Oncogenic Micrornas that are Associated with Colorectal Cancer, Cholangiocarcinoma and Hepatocellular Carcinoma in Patients with Primary Sclerosing Cholangitis Treated with High-Dose Ursodeoxycholic Acid (2017) (0)
Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: retrospective data analyses from the TRIO Network (2017) (0)
Iron‐mediated upregulation of M1 and downregulation of M2 programs in macrophages suggests a role for iron in the pathogenesis of non‐alcoholic steatohepatitis (1116.13) (2014) (0)
Benign Liver Tumors (2010) (0)
University of Birmingham Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis (2014) (0)
Elevated Serum Transferrin-Iron Saturation and Ferritin are Associated with Increased All-Cause Mortality in Metabolic Syndrome, While Moderate Alcohol Consumption is Protective in a Population-Based Cohort: Data from Nhanes III (2017) (0)
LIVER in heart-failure. (1951) (0)
The Relationship Between Obesity, Metabolic Syndrome and Iron Deficiency in NAFLD (2011) (0)
Reply (2020) (0)
Erratum (2013) (0)
652 Iron Excess Leads to Upregulation of NLRP3 Inflammasome, TLRS and NF-kB-Dependent Proinflammatory Activation in Primary Murine Dendritic Cells and in a Mouse Model of Nonalcoholic Fatty Liver Disease (2016) (0)
TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study (2022) (0)
Budd-Chiari Syndrome (2010) (0)
Liver Disease in Pregnancy (2010) (0)
Association between ursodeoxycholic acid therapy and prolonged transplant-free survival among patients with primary biliary cholangitis a number needed to treat analysis (2016) (0)
Ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: Panacea or placebo? (2004) (0)
1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis (2014) (0)
Portal Vein Variations and Anomalies (2010) (0)
P1147 : Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest cohorts (2015) (0)
Su1697 VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY VERSUS SHEAR-WAVE ULTRASOUND ELASTOGRAPHY COMPARED TO LIVER BIOPSY FOR THE ASSESSEMENT OF HEPATIC FIBROSIS: A STUDY IN 90 CONSECUTIVE PATIENTS (2020) (0)
Future developments in endoscopic imaging. (1995) (0)
Where do we go from HEIRS? (2006) (0)
Liver Function Tests (2010) (0)
Tu1685 Prevalence and Characteristics of a Large Cohort of >23,000 HCV Patients With a HCV Diagnosis in the Providence Health & Services System, a Major Health System in the Western United States (2016) (0)
Imaging Studies of the Liver (2010) (0)
P0787 : Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years of age vs younger HCV patients; Data from the Trio network (2015) (0)
The Evolving Use of Biochemical Markers in the Management of Primary Biliary Cholangitis: Discussion. (2021) (0)
P0460 : CD3hiCD4- Vγ9/Vδ2 TCR+ gamma delta T cells with Th1 and NK-like phenotype are induced in patients with chronic hepatitis B (2015) (0)
IDDF2019-ABS-0211 Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: an integrated analysis of phase 2 and 3 studies (2019) (0)
371 Serum Bile Acid Profiles After High-Dose Ursodeoxycholic Acid Treatment in Patients With Primary Sclerosing Cholangitis: Clinical Implications (2010) (0)
Field of Short Telomeres, Senescence, and Inflammation Associated Colorectal Cancer Arises in a − Ulcerative Colitis (2011) (0)
2474 Identification of Large Liver Mass of Unknown Origin (2019) (0)
Health-Related Quality of Life (HRQL) and Health Utilities (HU) of Patients with Chronic Hepatitis C (CH-C) Treated with an Interferon (IFN)-Free Regimen Containing Ledipasvir (LDV) and Sofosbuvir (SOF): 568 (2014) (0)
P1019 : The impact of metabolic syndrome on ALT levels among the large multiethnic cohort of North American patients with chronic hepatitis B infection enrolled in the Hepatitis B Research Network (HBRN) (2015) (0)
ERCP is effective in management of bile leaks in liver transplant recipients (1995) (0)
Response:: Letters to the Editor (2008) (0)
HMER_A_256692 83..92 (2021) (0)
You are what you wheat: effects of a whole-wheat diet compared with a refined-wheat diet on hepatic steatosis. (2018) (0)
Lesser Omentum and Variations in Form of the Liver (2010) (0)
Allogeneic transplants, Fas-signaling, and dysregulation of hepcidin (2013) (0)
Helicobacter pylori and peptic ulcer disease: issues for primary care providers. (1996) (0)
Updated estimate for prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin (2020) (0)
Capítulo 238 – Hepatitis C (2006) (0)
Bilirubin and Bile Acid Metabolism (2010) (0)
Arterial Blood Supply of the Liver, Biliary System, and Pancreas (2010) (0)
Iron overload (with attention to genetic testing and diagnosis/management of HFE wild type patients) (2006) (0)
Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC) (2022) (0)
Tu1033 Evaluation of Access to Care in Patients Prescribed Sofosbuvir-Containing Regimens: Data From the TRIO Network (2015) (0)
Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma. (2013) (0)
A population-based intervention to improve care cascade of patients with hepatitis C infection (2020) (0)
Vessel and Duct Distributions and Liver Segments (2010) (0)
Peformance of fibrometer-derived biomarker panels for assessment of fibrosis stage in NAFLD: NIMBLE stage 1 and the NASH CRN collaborative Study (2022) (0)
S1364 Effect of Cannabis on Mortality and Resource Utilisation in Patients With Acute on Chronic Liver Failure: Nationwide Analysis (2022) (0)
Albumin was best for preventing postparacentesis circulatory dysfunction in cirrhosis (1997) (0)
P1177 : Risk factors for hepatic decompensation in primary biliary cirrhosis - results of an international follow up study of 2326 patients (2015) (0)
Integrated Analysis of Controlled Clinical Trials Evaluating Efficacy and Safety of Sofosbuvir-Based Regimens in Chronic Hepatitis C Genotype 6 (HCV GT 6) (2017) (0)
DOES LOSARTAN REDUCE PORTAL PRESSURE AND DECREASE THE RISK OF VARICEAL HEMORRHAGE AMONG CIRRHOTIC PATIENTS (2001) (0)
incidence and Impact of Decompensating Events in Primary Biliary Cirrhosis - Results of an International Follow Up Study of 3030 Patients. : 73 (2015) (0)
Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase (2020) (0)
HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
Long Term Outcome of Endoscopic Management of Biliary Strictures Following Liver Transplantation (2004) (0)
2-1-2019 Ombitasvir , Paritaprevir , Ritonavir , and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease (2019) (0)
Initiation of methamphetamine abuse during interferon treatment. (2007) (0)
P163 IMMUNE CORRELATES OF VACCINE-MEDIATED PROTECTIVE IMMUNITY VERSUS VIRAL PERSISTENCE IN HEPATITIS B VIRUS INFECTION (2014) (0)
Capítulo 237 – Hepatitis B (2006) (0)
Letter: non‐invasive prediction models to exclude cirrhosis in NAFLD—not everyone fits the mould. Authors' reply (2022) (0)
Cohesins: Novel Markers for the Efficacy of Sorafenib in Hepatocellular Carcinoma (2014) (0)
Reply: (2008) (0)
Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitis (2018) (0)
HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
Hepatic transcriptomic analysis identifies a mast cell gene expression signature that correlates with fibrosis stage and is prognostic in patients with primary sclerosing cholangitis (2020) (0)
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis (2023) (0)
Early Treatment Response and Discontinuation Rates with Telaprevir and Boceprevir-based Triple Therapy in a Tertiary Care Liver Center: 428 (2013) (0)
Cell Types within the Liver (2010) (0)
Deficiencia en antitripsina-α 1 (2006) (0)
[Endoscopic management of biliary complications after liver transplantation]. (2005) (0)
Disorders of Bilirubin Transport (2010) (0)
What's Hot in the Red Journal This Month (2011) (0)
A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitis (2018) (0)
Outcomes of Treatment with Ledipasvir and Sofosbuvir Short Title : Ledipasvir / Sofosbuvir Baseline RASs and Treatment Outcomes (2016) (0)
How to approach an elevated ferritin level? (2002) (0)
Liver transplantation for metabolic disease (2007) (0)
Highlights in Primary Biliary Cholangitis From the EASL 2020 Digital International Liver Congress, the ACG 2020 Virtual Annual Scientific Meeting, and the AASLD 2020 Liver Meeting Digital Experience: Commentary. (2021) (0)
The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH (2022) (0)
Hepatic Artery Variations (2010) (0)
Is hepatic fibrosis reversible with therapy in hepatitis C? (2001) (0)
α1-Antitrypsin Deficiency (2010) (0)
Echinococcosis (Hydatid Disease) (2010) (0)
Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in non-alcoholic steatohepatitis phase 2a LIFT study (2022) (0)
Biomarkers, Imaging, and Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor-beta Selective Agonist, for 52 Weeks (2023) (0)
Tipos de células hepáticas (2006) (0)
Primary Biliary Cirrhosis (2010) (0)
Primary Sclerosing Cholangitis (2010) (0)
Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis (2020) (0)
Editorial: improved understanding of the epidemiology of primary biliary cirrhosis in South Korea (2016) (0)
Liver transplantation for metabplic liver diseases (2007) (0)
Clinical Manifestations of Cirrhosis (2010) (0)
FOR MICRORNA ISOLATION FROM CLINICAL SERUM SAMPLES (2012) (0)
Consensus Statement on the definition and classification of metabolic hyperferritinaemia (2023) (0)
Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis (2018) (0)
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe (2022) (0)
Cost-Effectiveness of Entecavir vs. Lamivudine with Adefovir Salvage as First-Line Treatment in HBeAg-Positive Chronic Hepatitis B: Analyses Based on Two-Year Results from a Randomized Clinical Trial (2005) (0)
T1006 Histologic Evidence of Active Liver Injury in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B Patients with Normal or Minimally Elevated Alanine Transaminase (2008) (0)
Microsatellite Instability and K-ras Mutations Associated with Pancreatic Adenocarcinoma and Pancreatitis1 (2006) (0)
Moving from early to moderate or advanced biochemical disease stage during follow-up is associated with an increasing risk of clinical events in primary biliary cholangitis patients (2017) (0)
BRIEF COMMUNICATIONS High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B (2012) (0)
Pediatric cholestatic liver disease: Successful transition of care (2019) (0)
Developing clinical research in a clinical hepatology practice (2017) (0)
Cirrosis biliar primaria (2006) (0)
FRI-021-Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis (2019) (0)
An oral treatment for iron overload in thalassemia? (1996) (0)
What Are the Best Diagnostic Modalities for Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis? A Summary of AALSD Trend Conference in NASH (154/120) (2020) (0)
NOD/SCID mice Transplantation of allogeneic T cells alters iron homeostasis in (2011) (0)
Bile Duct Cancer (2010) (0)
Sofosbuvir/Velpatasvir Plus GS-9857 (100 Milligrams) for 6, 8, or 12 Weeks in Genotype 1-6 Hepatitis C Virus (HCV)-Infected Patients: An Integrated Analysis of Safety and Efficacy From Two Phase 2 Studies (2016) (0)
Topography of the Liver (2010) (0)
Chapter 16 – Hemochromatosis (2012) (0)
S1844 Hepatic Hepcidin Expression in an Obese Diabetic Model of Nonalcoholic Steatohepatitis (NASH) (2010) (0)
Curcumin and turmeric as preventive agents for iron‐related carcinogenesis. (2013) (0)
Genetic Markers Predisposing to Nonalcoholic Steatohepatitis. (2023) (0)
Genome-Wide Transcriptomic Profiling Reveals Novel Micrornas and Specific Microrna Signatures Associated with Liver Inflammation, Cirrhosis and Hepatocellular Carcinoma in Plasma of Patients with Primary Sclerosing Cholangitis (2017) (0)
Validation of the ADAPT score for the diagnosis of clinically significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) (2022) (0)
Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis. (2023) (0)
PIN3 THE COST OF TREATING RIBAVIRIN-INDUCED ANEMIA IN HEPATITIS C: THE IMPACT OF USING RECOMBINANT HUMAN ERYTHROPOETIN (2006) (0)
Su1357: PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH LONG-TERM OBETICHOLIC ACID IN A TRIAL-SETTING DEMONSTRATE BETTER EVENT-FREE SURVIVAL OUTCOMES THAN EXTERNAL CONTROLS FROM THE GLOBAL PBC AND UK-PBC STUDY GROUPS (2022) (0)
PE-056 : The Safety and Tolerability of SOF/VEL/VOX for 8/12 Weeks in >1,000 Patients Treated in the POLARIS Studies: An Integrated Analysis (2017) (0)
Fibrosis Progression Rate in Biopsy-proven Nonalcoholic Fatty Liver Disease among People with Diabetes versus People without Diabetes: A Multicenter Study. (2023) (0)
Elevated Serum Ferritin Values Above the Upper Limit of Normal Are Associated With Laboratory and Histologic Evidence of Increased NASH Severity, but Not the Presence of Diabetes or Metabolic Syndrome Among Patients in the NASH CRN (2011) (0)
Sa1295 Serum MicroRNA: Novel Prognostic Biomarkers in Primary Sclerosing Cholangitis Patients Treated With High-Dose Ursodeoxycholic Acid (2013) (0)
Transjugular intrahepatic portosystemic shunt. (2016) (0)
Outcomes in Patients Receiving High Dose Ursodeoxycholic Acid Are Not Dependent on Disease Status (2011) (0)
P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies (2017) (0)
Hedgehog Pathway Targeted by Vitamin E Therapy in NASH Defining Optimal Laboratory Response Criteria in UDCA Treated Primary Biliary Cirrhosis. Results of an International Multicenter Long-term Follow-up Study (2013) (0)
Tu1565 – Clinical Utility and Application of Noninvasive Tests of Fibrosis in the Selection of Patients with Advanced Fibrosis Due to Nash in the Phase 2 Atlas Trial (2019) (0)
606 Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-infected with HCV and HIV: Real-world Heterogeneous Population from the TRIO Network (2016) (0)
CORTICOSTEROIDS FOR ALCOHOLIC LIVER DISEASE: STRENGTH IN NUMBERS? (2002) (0)
Spontaneous Bacterial Peritonitis. (2015) (0)
Colangitis esclerosante primaria (2006) (0)
Review: magnetic resonance cholangiopancreatography is accurate for diagnosing biliary disease. (2004) (0)
LBP-30-Changes in Serum Bile Acids Correlate with 7alpha-Hydroxy-4-Cholesten-One and Fibrogenesis Biomarker Pro-C3 with NGM282 Therapy in Patients with Non-alcoholic Steatohepatitis (2019) (0)
Isolation and Characterization of Iron Binding Compounds from Turmeric (Curcuma longa) (2015) (0)
Comparison of hepatic iron content in African Americans and Caucasians with hepatitis C. (2001) (0)
Biochemical patterns of alkaline phosphatase and bilirubin levels in relation to clinical outcomes in UDCA-treated PBC patients- an international study (2016) (0)
Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study: 364 (2013) (0)
Reply (2011) (0)
defovir Dipivoxil Alone or in Combination With Lamivudine in atients With Lamivudine-Resistant Chronic Hepatitis B (2003) (0)
S1302 Effect of Bed Size of the Hospital on the Risk of Development of Acute on Chronic Liver Failure (ACLF) in Patients With Decompensated Cirrhosis (2022) (0)
A prospective study of the phenotypic characteristics of patients referred for iron overload (2003) (0)
S1141 Gaps in the Patient Journey Through the Diagnosis and Management of Primary Biliary Cholangitis (2021) (0)
Tu1013 On-Treatment HCV RNA As a Predictor of Sustained Virologie Response in HCV Genotype 3 - Infected Patients Treated With Daclatasvir and Sofosbuvir: Analysis of Phase 3 Ally-3 Study (2015) (0)
SAT-315-Clinical utility and application of non-invasive tests of fibrosis in the selection of patients with advanced fibrosis due to NASH in the Phase 2 ATLAS trial (2019) (0)
Estimation of the human liver volume and configuration using three-dimensonal ultrasonography: effect of a high-caloric liquid meal (1998) (0)
O216: Treating decompensated cirrhotics (2014) (0)
T1869 The Changing Face of Primary Sclerosing Cholangitis (2009) (0)
Update on therapy for hepatobiliary diseases. (1996) (0)
Treatment Targets and Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH): A Summary of AALSD Trend Conference in NASH (2020) (0)
Impact of pruritus in primary sclerosing cholangitis (PSC): a multinational survey (2022) (0)
IκB kinase ε: A potential therapeutic target for obesity (and nonalcoholic fatty liver disease)? (2010) (0)
Superficies y lecho hepático (2006) (0)
Su1351: TREATMENT WITH SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND PRIOR EXPERIENCE WITH OBETICHOLIC ACID OR FIBRATES (2022) (0)
Irrigación sanguínea arterial del hígado, sistema biliar y páncreas (2006) (0)
STEATOHEPATITIS / METABOLIC LIVER DISEASE Serum Ferritin Is an Independent Predictor of Histologic Severity and Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2011) (0)
Ethnic Differences in Cryptogenic Cirrhosis in Patients Undergoing Liver Transplantation: 348 (2005) (0)
Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid (2023) (0)
S1871 The Association of Low Level of Both Vitamin a and Retinol Binding Protein With the Liver Complications in Patients With Primary Sclerosing Cholangitis (2010) (0)
THU-194-Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies (2019) (0)
Reply: To PMID 21953442. (2013) (0)
Optimising trial design in late-stage primary biliary cholangitis : evaluating options for composite clinical endpoint studies (2019) (0)
PMC10 AN INTERNET-BASED EDUCATIONAL INTERVENTION TO INCREASE KNOWLEDGE: A RAPID, EFFICIENT, AND EFFECTIVE METHOD (2005) (0)
Rusfertide (PTG-300), a Hepcidin Mimetic, Maintains Liver Iron Concentration in the Absence of Phlebotomies in Patients with Hereditary Hemochromatosis (2021) (0)
Hepatocytes from Embryonic Stem Cells (2007) (0)
Validation of the accuracy of the fast score for detecting non-alcoholic steatohepatitis patients at high risk of becoming cirrhotic in a North American cohort (2020) (0)
Pioglitazone reduced liver injury and improved fasting glucose in nonalcoholic steatohepatitis without diabetes (2009) (0)
S1845 Combining Genetic and Dietary Factors in Creation of a Novel Model of Nonalcoholic Steatohepatitis (NASH) in Mice (2010) (0)
Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis (2018) (0)
Response: (2008) (0)
Comparison of clinical prediction rules for detection of cirrhosis in non-alcoholic fatty liver disease: a multicenter, international, collaborative study- NASH CRN (USA) and Newcastle (UK) Cohort (2017) (0)
University of Birmingham A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) (0)
THU-024-Methylation signatures in blood show accelerated epigenetic aging in patients with primary sclerosing cholangitis compared to healthy controls (2019) (0)
Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database (2022) (0)
The impact of geographical region on outcomes of patients with primary biliary cholangitis from western Europe (2020) (0)
Increase in age at diagnosis of primary biliary cholangitis over the last 40 years (2017) (0)
Hemochromatosis and Iron Storage Disorders (2017) (0)
Iron Excess Leads to Inflammatory Activation in T Cells in Vitro and Upregulation of Hepatic T Cell Markers in a Mouse Model of Nonalcoholic Steatohepatitis and Patients with NASH (2017) (0)
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study (2023) (0)
Isolation and characterization of iron chelators from turmeric (Curcuma longa): selective metal binding by curcuminoids (2017) (0)
Treating NAFLD: Future Prospects. (2006) (0)
Mo1448 OBETICHOLIC ACID IMPROVES TRANSAMINASES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE 18-MONTH INTERIM ANALYSIS OF THE REGENERATE STUDY (2020) (0)
DOES EARLY TREATMENT OF ACUTE HEPATITIS C VIRUS INFECTION WITH INTERFERON ALFA-2B PREVENT THE DEVELOPMENT OF CHRONIC HEPATITIS? (2002) (0)
Tu1016 Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 (2015) (0)
O215: Interferon‐free direct‐acting antiviral (DAA) regimens for treatment of chronic hepatitis C (2014) (0)
Time trends in major hepatic complications in primary biliary cholangitis : incidence and transplant-free survival (2017) (0)
It TAK(es) 1 to prevent steatohepatitis and tumorigenesis. (2014) (0)
A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis (2022) (0)
TACG_A_269622 353..361 (2021) (0)
post-pneumonectomy patients Airway obstruction complicating esophageal stent placement in two (2013) (0)
LIVER Ef fi cacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid (2015) (0)
Third-trimester tenofovir to prevent mother-to-child hepatitis B virus transmission (2017) (0)
An Integrated analysis of phase 2,3 SOF and LDV/SOF trials for the treatment of GT6 HCV infection (2016) (0)
Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase (2020) (0)
Hepatitis Caused by Other Viruses (2010) (0)
Synopsis for the Yale Workshop on Hepatocellular Carcinoma. (2002) (0)
Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis– the Global PBC Study Group (2018) (0)
Metabolic liver diseases (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kris V. Kowdley?

Kris V. Kowdley is affiliated with the following schools:

Washington State University
University of Washington